welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
researchers
Eugene Gerner, PhD
Researcher Director
Gastrointestinal Cancer Program
Arizona Cancer Center
Tucson, Arizona, United States
CEO, Cancer Prevention Pharmaceuticals (CPP)
Cancer Prevention Pharmaceuticals (CPP) is a company in the late stages of developing drugs and drug combinations to treat people with risk factors for cancer. Some of these people have genetic risk factors, such as defects in the adenomatous poly posits coli tumor suppressor gene which cause the familial adenomatous polyposis (FAP) syndrome. Others have sporadic risk factors, such as prior colorectal cancer or neuroblastoma with amplified copies of the MYCN oncogene. CPP is also developing companion diagnostics for its drug therapies.
expertly curated content related to this topic
-
Randall E. Brand, MDProfessor of Medicine Academic Director...
-
Deborah W. Neklason, PhDDeborah Neklason, PhD, is a member of Hu...
-
Brindusa Truta, MAS, MDDr. Brindusa Truta, MAS, MD is an Assist...
-
Uri Ladabaum, MDUri Ladabaum, MD is a Professor of Medic...
-
deb neklason, phdResearch Associate Professor, Division o...
-
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposisIn a randomized clinical chemoprevention...
-
Fokko M. NagengastTeacher at Wageningen University, Divisi...